Loading...
OTCM
GTHP
Market cap20mUSD
Jul 10, Last price  
0.26USD
1D
-5.45%
1Q
160.26%
Jan 2017
-51.73%
Name

Guided Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
10,258.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
76.98%
Rev. gr., 5y
-43.90%
Revenues
2k
-97.96%
983,000977,0001,037,0001,317,0001,550,0003,364,0003,597,0003,410,0001,179,000823,000606,000605,000244,00057,00036,000102,00081,00013,00098,0002,000
Net income
-3m
L-25.74%
-2,070,000-4,948,0003,016,000-4,810,000-6,212,000-2,846,000-6,644,000-4,353,000-7,215,000-9,883,000-6,902,000-3,970,000-10,696,0001,016,000-3,381,000-1,335,000-3,727,000-4,972,000-3,489,000-2,591,000
CFO
-1m
L-35.91%
-3,507,000-3,575,000-3,944,000-1,909,000-1,420,000-347,000-2,734,000-3,666,000-5,556,000-6,283,000-4,043,000-1,802,000-1,144,000-1,365,000-806,000-1,875,000-1,592,000-1,478,000-1,746,000-1,119,000
Earnings
Aug 12, 2025

Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
URL
https://www.guidedinc.com/
IPO date
Jul 01, 1997
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2
-97.96%
98
653.85%
13
-83.95%
Cost of revenue
2,110
3,555
3,346
Unusual Expense (Income)
NOPBT
(2,108)
(3,457)
(3,333)
NOPBT Margin
Operating Taxes
174
631
Tax Rate
NOPAT
(2,282)
(3,457)
(3,964)
Net income
(2,591)
-25.74%
(3,489)
-29.83%
(4,972)
33.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
835
436
3,720
BB yield
-9.71%
-5.56%
-38.15%
Debt
Debt current
2,047
1,483
888
Long-term debt
265
912
1,700
Deferred revenue
Other long-term liabilities
2
5
Net debt
1,924
1,804
275
Cash flow
Cash from operating activities
(1,119)
(1,746)
(1,478)
CAPEX
(31)
Cash from investing activities
(31)
Cash from financing activities
916
24
3,180
FCF
(1,209)
(2,415)
(5,863)
Balance
Cash
388
591
2,313
Long term investments
Excess cash
388
586
2,312
Stockholders' equity
(150,152)
(144,657)
(140,841)
Invested Capital
147,422
143,000
140,226
ROIC
ROCE
77.22%
208.63%
541.95%
EV
Common stock shares outstanding
57,339
51,131
32,505
Price
0.15
-2.28%
0.15
-48.83%
0.30
-48.29%
Market cap
8,601
9.58%
7,849
-19.51%
9,752
25.64%
EV
10,630
12,673
13,108
EBITDA
(2,013)
(3,372)
(3,261)
EV/EBITDA
Interest
381
278
582
Interest/NOPBT